Drug Profile
Research programme: protein therapeutics - Innate Biologics
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Innate Biologics; Wistar Institute
- Class Anti-inflammatories; Antineoplastics; Proteins
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Cancer in USA
- 28 Apr 2022 No recent reports of development identified for research development in Inflammation in USA
- 21 Mar 2018 Early research in Cancer in USA (unspecified route)